谢方云 职务：
职称：教授、主任医师、博士生导师
专长：鼻咽癌、舌癌、喉癌、下咽癌、牙龈癌、扁桃体癌等头颈肿瘤综合治疗

主要简介 详细介绍 预约挂号

一、基本情况
职称：教授、主任医师、博士生导师
专业特长：鼻咽癌、舌癌、喉癌、下咽癌、牙龈癌、扁桃体癌等头颈肿瘤综合治疗
专家门诊时间：周二下午、周三上午
主攻方向如下：①鼻咽癌的调强放射治疗、图像引导放射治疗及自适应放疗；②鼻咽癌调强放射治疗及个体化精准治疗；③头颈部肿瘤的调强放射治疗及综合治疗
二、学习及工作经历
1980.09-1985.07　湖南医学院　临床医学　本科　获学士学位
1990.09-1994.07　中山医科大学　肿瘤学　获硕士学位
2002.08-2011.12　中山大学肿瘤防治中心　放疗科　副主任医师
2011.12-2016.12　中山大学肿瘤防治中心　放疗科　主任医师
2016.12-至今　　中山大学肿瘤防治中心　放疗科　教授、主任医师
三、学术兼职
广东省医师协会放射治疗专业委员会副主任委员
广东省医师协会放射治疗专业委员会头颈肿瘤专业组组长
粤港澳大湾区放射治疗医师联盟副主任
华人肿瘤放射治疗协作组第一届放射免疫工作委员会常委
四、获奖情况
(1) 鼻咽癌综合诊疗方案的建立与临床应用 2020年 教育部高校科技进步奖一等奖
(2) 提高鼻咽癌疗效的关键技术与应用 2020年 广东省医学科学技术奖一等奖
(3) 鼻咽癌诊疗关键策略研究与应用 2015年 国家科学技术进步奖二等奖
(4) 鼻咽癌个体化治疗研究与应用 2014年 中华医学科技奖一等奖
(5) 鼻咽癌个体化治疗研究与应用 2014年 高等教育部科技进步奖一等奖
(6) 鼻咽癌个体化治疗研究与应用 2014年 广东省科学技术奖励一等奖

一、基本情况
职称：教授、主任医师、博士生导师
专业特长：鼻咽癌、舌癌、喉癌、下咽癌、牙龈癌、扁桃体癌等头颈肿瘤综合治疗
专家门诊时间：周二下午、周三上午
主攻方向如下：①鼻咽癌的调强放射治疗、图像引导放射治疗及自适应放疗；②鼻咽癌调强放射治疗及个体化精准治疗；③头颈部肿瘤的调强放射治疗及综合治疗
二、学习及工作经历
1980.09-1985.07　湖南医学院　临床医学　本科　获学士学位
1990.09-1994.07　中山医科大学　肿瘤学　获硕士学位
2002.08-2011.12　中山大学肿瘤防治中心　放疗科　副主任医师
2011.12-2016.12　中山大学肿瘤防治中心　放疗科　主任医师
2016.12-至今　　中山大学肿瘤防治中心　放疗科　教授、主任医师
三、学术兼职
广东省医师协会放射治疗专业委员会副主任委员
广东省医师协会放射治疗专业委员会头颈肿瘤专业组组长
粤港澳大湾区放射治疗医师联盟副主任
华人肿瘤放射治疗协作组第一届放射免疫工作委员会常委
四、获奖情况
(1) 鼻咽癌综合诊疗方案的建立与临床应用 2020年 教育部高校科技进步奖一等奖
(2) 提高鼻咽癌疗效的关键技术与应用 2020年 广东省医学科学技术奖一等奖
(3) 鼻咽癌诊疗关键策略研究与应用 2015年 国家科学技术进步奖二等奖
(4) 鼻咽癌个体化治疗研究与应用 2014年 中华医学科技奖一等奖
(5) 鼻咽癌个体化治疗研究与应用 2014年 高等教育部科技进步奖一等奖
(6) 鼻咽癌个体化治疗研究与应用 2014年 广东省科学技术奖励一等奖
五、主持科研项目
①国家自然科学基金重点项目 cdh1(FZR1)磷酸化新点被调控的机理，对功能的影响及其意义(2009-2013年，第2负责人)
②国家自然科学基金面上项目 Fli-1靶向上调VEGF-C促进鼻咽癌转移的分子机制和临床意义研究（2017-2020年 第1负责人）
③广东省自然科学基金 Fli-1靶向调控VEGF-C促进鼻咽癌生长和转移的研究（2017-2020，第1负责人）
④广东省科学技术厅 多西他赛加顺铂（TP）对比单药顺铂（DDP）的同期化疗联合调强放疗治疗高危局部区域晚期鼻咽癌的随机对照II期临床研究（2016-2018年，第1负责人）
⑤中山大学5010项目 调强放疗加或不加同期化疗治疗II期鼻咽癌的非劣效性、随机对照、多中心III期临床研究（2015-2025年，第1负责人）
六、第一及或通讯作者发表SCI文章
1. Xiang-Bo Wan, Rou Jiang, Fang-Yun Xie (Co-first authors), Zhen-Yu Qi, Ai-Ju Li, Wei-Jun Ye, Yi-Jun Hua, Yu-Liang Zhu, Xiong Zou, Ling Gao, Hai-Qiang Mai, Xiang Guo, Ming-Huang Hong, Ming Yuan Che. Endoscope—guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma. PLoS One 2014;9;e90048.(IF 2.806)
2. Xiao-Bin Lv, Fangyun Xie (Co-first authors), Kaishun Hu, Yuanzhong Wu, Lin-Lin Cao, Xia Han, Yi Sang, Yi-Xin Zeng, and Tiebang Kang. Damaged DNA-binding protein 1(DDB1) interacts with Cdhl and modulates the function of APC/CCdhl. J Biol Chem 2010; 285:18234-18240.（IF 4.125）
3. Pu-Yun OuYang, MD, Lu-Ning Zhang, MD, Jie Tang, MD, Xiao-Wen Lan, MD, Yao Xiao, MD, Yuan-Hong Gao, MD, and Fang-Yun Xie, Md. Evaluation of Body Mass Index and Survival of Nasopharyngeal Carcinoma by Propensity-Matched Analysis: An Observational Case-Control Study. Medicine (Baltimore)2016;95:e2380(IF 1.803)
4. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng,Pu-Yun OuYang, Fang-Yun Xie. Propensity score matching analysis of cisplatin-based concurrent chemotheraoy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotheraphy era. Oncotarget 2015;6:44019-44029(IF 5.168)
5. P-Y OuYang, L-N Zhang, X-W Lan, C Xie, W-W Zhang, Q-X Wang, Z Su, J Tang and F-Y Xie. The significant survival advantage of female sex in nasopharyngeal carcinoma:a propensity-matched analysis. Br J Cancer 2015;112:1554-1561(IF 6.176)
6. Lu-Ning Zhang, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Pretreatment anemia and survival in nasopharyngeal carcinoma. Tumour Biol 2015(IF 3.65)
7. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun Ouyang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT:a retrospective study. Tumour Biol 2015(IF 3.65)
8. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Pu-Yun OuYang, Fang-Yun Xie. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol 2015;51:950-956(IF 4.794)
9. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Xiao-Wen Lan and Fang-Yun Xie. Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC Cancer 2015;15:429(IF 3.288)
10. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Fang-Yun Xie. Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. PLoS One2015;10:e**（IF 2.806）
11. Xue-Xia Liang, Qun Li, Zhen Su, Xiao-Wen Lan, Pu-Yun OuYang, Yan-Ping Mao, Ding-Bo Shi, Wu-Guo Deng, Zhi-Bin Cheng, Si-Yang Wang, Fang-Yun Xie. Significant prognostic impact of chemoradiatherapy-induced hemoglobin decrease on treatment outcomes of nasopharyngeal carcinoma. J Cancer 2015;6;:502-510(IF 2.916)
12. Pu-Yun OuYang, Zhen Su, Jie Tang, Xiao-Wen Lan, Yan-Ping Mao,Wuguo Deng, Fang-Yun Xie. Diabetes,Prediabetes and the Survival of Nasopharyngeal Carcinoma:A Study of 5,860 Patients. PLoS One2014;9:e111073(IF 2.806)
13. Xuexia Liang, Dingbo Shi, Jingping Yun, Yanping Mao,Puyun Ouyang, Zhen Su, Jia Fu, Jinghui Hou, Wuguo Deng and Fangyun Xie. Friend leukemia virus integration 1 expression has prognostic significance in nasopharyngeal carcinoma. Transl Oncol 2014;7:493-502(IF 3.025)
14.P.Y.OuYang,C.Xie,Y.P.Mao,Y.Zhang,X.X.Liang,Z.Su,Q.Liu&F.Y.Xie. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-2146(IF 11.855)
15. P-Y OuYang, Z Su, Y-P Mao, Q Liu and F-Y Xie. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer 2013;109:2462-2466(IF 6.176)
16. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Xue-Xia Liang, Qing Liu, Wu-Guo Deng, and Fang-Yun Xie. Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer 2013;109:788-794(IF 6.176)
17. P-Y OuYang, Z Su,X-H Ma, Y-P Mao, M-Z Liu and F-Y Xie. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer 2013;109:2987-29979（IF 6.176）
18. P-Y OuYang, Z Su, Y-P Mao, X-X Liang, Q Liu and F-Y Xie. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma.Cancer Epidemiol Biomarkers Prev 2013;22:2285-2294(IF 6.176)
19. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie. Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC:A Meta-Analysis. PLoS One2018;8:e79000(IF 2.806)
20. Xin Wang, Yi Liang, Qiong Chen, Hui-Min Xu, Nan Ge,Rong-Zhen Luo, Jian-Yong Shao, Zhi-Wei He, Yi-Xin Zeng, Tiebang Kang, Jing-Ping Yun &Fangyun Xie. Prognostic significance of SOX2 exoression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85(IF 2.007)
21. Hui-Min Xu, Yi Liang, Qiong Chen, Qi-Nian Wu, Yun-Miao Guo, Guo-Ping Shen, Ru-Hua Zhang, Zhi-Wei He, Yi-Xin Zeng, Fang-Yun Xie, and Tie-Bang Kang. Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer2011;30:204-212(IF 4.111)
22. Pu-Yun OuYang, Dingbo Shi, Rui Sun, Yu-Jia Zhu, Yao Xiao,Lu-Ning Zhang, Xu-Hui Zhang, Ze-Ying Chen, Xiao-Wen Lan, Jie Tang, Yuan-Hong Gao, Jun Ma, Wuguo Deng, Fang-Yun Xie. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma. Oncotarget. 2016 Apr 4.(IF 5.168)
23. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumor Biol. 2016 Apr;37(4):4429-38(IF 3.65)
24. Pu-Yun OuYang, Zhuo-Fei Bi, Lu-Ning Zhang, Kai-Yun You, Yao Xiao, Xiao-Wen Lan, Jie Tang, Xi-Cheng Wang, Wuguo Deng and Fang-Yun Xie. Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study. Transl Oncol. 2016; 9(4):329-335.(IF 3.025)
25. Xiao-Wen Lan, Xue-Bin Zou, Yao Xiao, Jie Tang, Pu-Yun OuYang, Zhen Su, Fang-Yun Xie. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage Iva-b Nasopharyngeal Carcinoma:Plos One.2016;11(8):e**.(IF 2.806)
26. Lei Chen, Chao-Su Hu, Xiao-Zhong Chen, Guo-Qing Hu, Zhi-Bin Cheng, Yan Sun, Wei-Xiong Li, Yuan-Yuan Chen, Fang-Yun Xie, Shao-Bo Liang, Yong Chen, Ting-Ting Xu, Bin Li, Guo-Xian Long, Si-Yang Wang, Bao-Min Zheng, Ying Guo, Ying Sun, Yan-Ping Mao, Ling-Long Tang, Yu-Ming Chen, Meng-Zhong Liu, Jun Ma.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomiased controlled trial. Lancet Oncol2012;13:163-71(IF 33.9)
27. Ying Sun, Wen-Fei Li, Nian-Yong Chen, Ning Zhang, Guo-Qing Hu, Fang-Yun Xie (Co-first authors), Yan Sun, Xiao-Zhong Chen, Jin-Gao Li, Xiao-Dong Zhu. Chao-Su Hu, Xiang-Ying Xu, Yuan-Yuan Chen, Wei-Han Hu, Ling Guo, Hao-Yuan Mo, Lei Chen, Yan-Ping Mao, Rui-Sun, Ping Ai, Shao-Bo Liang, Guo-Xian Long, Bao-Min Zhang, Xing-Lai Feng, Xiao-Chang Gong, Ling Li, Chun-Ying Shen, Jian-Yu Xu, Ying Guo, Yu-Ming Chen, Dan Zhang, Li Lin, Ling-Long Tang, Meng-Zhong Liu, Jun Ma. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. Lancet Oncol 2016:1470-2045(IF 33.9)
28. Xiao-Wen Lan, Yao Xiao, Xue-Bin Zou, Pu-Yun OuYang, Fang-Yun Xie. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. OncoTargets and Therapy 2017:10 3853-3860(IF 2.3184)
29. Pu-Yun OuYang, Yao Xiao, Kai-Yun You, Lu-Ning Zhang, Xiao-Wen Lan, Xiao-Min Zhang, Fang-Yun Xie. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017; 72: 65-72. (IF 4.794)
30. Pu-Yun OuYang, Lu-Ning Zhang, Yao Xiao, Xiao-Wen Lan, Xiao-Min Zhang, Jun Ma, Fang-Yun Xie. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma. Oral Oncol 2017;67:37-45.(IF 4.794)
31. Zhen Su, Zhan-Wen Guo, Yan-Ping Mao, Jie tang, Xiao-Wen Lan, Fang-Yun Xie, Qun Li. Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution. J Cancer 2017 Apr 9;8(6):1097-1102. （IF 2.916）
32. OuYang PY, Zhang XM, Qiu XS, Liu ZQ, Lu L, Gao YH, Xie FY. A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma. Oncol 2019 (IF 5.306）
33. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. (IF 74.699）

更新日期：2021年4月30日